drugset / Trial / NCT03464864

Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers

NCT03464864

Phase 1 Completed 36 enrolled Mannkind Corporation
Non-randomizedSingle-groupOpen-labelOther

Summary

A Dose-Rising Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers

Timeline

Start
2018-03-09
Primary completion
2018-06-05
Completion
2018-06-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Treprostinil Other / unclassified 30 ug Inhaled
Subject Treprostinil Other / unclassified 60 ug Inhaled
Subject Treprostinil Other / unclassified 90 ug Inhaled
Subject Treprostinil Other / unclassified 120 ug Inhaled
Subject Treprostinil Other / unclassified 150 ug Inhaled
Subject Treprostinil Other / unclassified 180 ug Inhaled
Subject Treprostinil Other / unclassified 240 ug Inhaled
Subject Treprostinil Other / unclassified 300 ug Inhaled